Please login to the form below

fedratinib

This page shows the latest fedratinib news and features for those working in and with pharma, biotech and healthcare.

It also comes on the heels of another significant approval of Celgene’s JAK inhibitor Inrebic (fedratinib), which scored an FDA nod in August.

Roche agrees $1.4bn takeover of fibrosis specialist Promedior

fedratinib) which was cleared by the FDA in August.
BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

That deal is worth up to $7bn but is weighted to fedratinib’s commercial performance, with $1.4bn tied to regulatory approvals in myelofibrosis and other indications. ... Impact was originally formed in 2016 after the acquisition of the rights to
Triplet approvals for myeloma boost Celgene in Q2

Also nearing the market are fedratinib for myelofibrosis which could be approved in September, luspatercept for myelodysplastic syndromes – with an FDA decision due next April – and ozanimod for multiple sclerosis, which
BMS and Celgene announce $74bn merger

It also TYK2 and ozanimod in immunology and inflammation, and two more in haematology: luspatercept and fedratinib.
Celgene to launch five new products through to 2020

The five blockbusters-in-waiting are multiple sclerosis therapy ozanimod – which has been delayed by the FDA’s refusal to accept the company’s regulatory filing earlier this year – fedratinib for

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

20 for 2020 – Five pharma companies to watch

Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis
Deal Watch January 2018

This is a high percentage. Interestingly Impact was originally formed in 2016 after the acquisition of the rights to fedratinib from Sanofi. ... Acquisition company - remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2
Pharma deals during November 2013

While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

No results were found

Add my company

Healing the Healers: Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs: It’s not a question of ‘if,’ it’s a question of ‘when.’...
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment: Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Email:
Password: